An observational study in Systemic Lupus Erythematosus, sponsored by Sohag University. Status unknown at 1 site in Egypt. Open to participants aged 17 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-09.
Sponsored by Sohag University · Observational
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that involve many different organs and display a variable clinical course.The prevalence of SLE varies across gender, race/ethnicity, and geographic regions. SLE demonstrates a striking female predominance with a peak incidence of disease during the reproductive years. In adults, the female to male ratio is 10- Renal involvement is common in SLE and is a significant cause of morbidity and mortality. It is estimated that as many as 90% of patients with SLE will have pathologic evidence of renal involvement on biopsy, but clinically significant nephritis will develop in only 50%. AII is a potent pro-inflammatory modulator with the ability to augment the immune responses in renal and non-renal tissues. Specifically in the kidney, AII stimulates mononuclear cells, favoring hyperplasia and hypertrophy of mesangial, tubular cells and interstitial fibroblasts, and increases expression and synthesis of the extracellular protein matrix leading to fibrosis.
Angiotensin II and strong candidate for a mediator of the development and progression of renal disease in SLE has been found to promote glomerular cell proliferation, alter growth factor expression, and activate proinflammatory cytokines, all of which promote glomerulosclerosis
1,202 studies on the registry are indexed under Lupus Erythematosus, Systemic; 399 are open to participants now.
This study's planned enrollment of 75 is below the median of 140 across 283 observational studies indexed under Lupus Erythematosus, Systemic.
Browse Lupus Erythematosus, Systemic studies →Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will include 50 patients diagnosed by 2019 American College of Rheumatology/European League Against Rheumatism classification criteria as systemic lupus erythematosus, 25of them will be selected as Lupus Nephritis (LN).
Exclusion Criteria:
systemic lupus erythematosus patients
Diagnostic Test: Angiotensin Converting Enzyme test
healthy individuals
Diagnostic Test: Angiotensin Converting Enzyme test
blood sample is taken SLE patients , healthy control , ACE level will be measured by ELISA kits
Angiotensin Converting Enzyme test
laboratory test, ELISA kits, measure serum levels of angiotensin converting enzyme in SLE patients , control
Time frame: 3 months
protein creatine ratio
laboratory test, urine sample used to measure amount of proteinurea
Time frame: 3 months
serum creatine test
lab test , to asses renal function
Time frame: 3 months
Anti nuclear Anti body tset
lab tset, IF technique, for diagnosis of SLE disease
Time frame: 3 months
anti ds-DNA test
lab test , for diagnosis of SLE , lupus nephritis
Time frame: 3 months
Plan to share: Yes
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic→
Sohag University